Highlights

  • Shield Therapeutics shares gained about 320% over year.
  • Rising ACCRUFeR prescriptions and US label expansion supported revenue momentum.
  • The company remains dependent on a single product while continuing to report cash outflows.

Shield Therapeutics plc (LSE:STX) has delivered a sharp rise in its share price over the past year. The stock climbed from around 2.63 GBp to nearly 11 GBp, translating into a gain of roughly 318%. This sustained rally lifted the company’s market capitalisation beyond GBP 100m, marking a shift from penny stock status to the pharmaceutical small-cap segment.

As of January 12, 2026, the shares were trading near 10.50 GBp, up 2.38% on the day. Over shorter periods, performance was mixed but largely positive, with no change over the past week, a 2.44% rise over one month, and gains of 31.25% over three months. Medium-term momentum remained elevated, with the stock up 195.77% over six months and about 320% year-on-year.

The 52-week high of 12.50 GBp was recorded on December 22, 2025, while the 52-week low stood at 2.10 GBp in April 2025, highlighting the scale of the rebound during the year.

ACCRUFeR Supports Revenue Growth
Shield Therapeutics is a commercial-stage pharmaceutical company focused on iron deficiency treatments. Its lead product, ACCRUFeR, is the only oral iron therapy approved by the US Food and Drug Administration for both iron deficiency and iron deficiency anaemia.

In December, the FDA expanded the product’s approval to include adolescent patients following phase three paediatric trial results. This broadened the eligible patient base in the US, where iron-related conditions affect more than 20 million people.

During the third quarter of 2025, active ACCRUFeR subscriptions increased to around 54,000. Net revenue reached USD 13.1m for the quarter, reflecting an 82% year-on-year increase driven by higher prescription volumes.

Market Size and Geographic Reach
The global iron deficiency treatment market is estimated at around USD 5.6bn and is projected to reach USD 10.9bn by 2034. ACCRUFeR currently holds approval in the US, while a regulatory review in Europe is expected later in the year, which could expand geographic reach without adding new products.

Despite growing subscriptions, revenue remains concentrated in a single therapy, indicating limited product diversification at this stage.

Cash Position and Business Exposure
Shield Therapeutics continues to report operating losses, although these have narrowed. The company has indicated expectations of achieving free cash flow positivity in 2026, with earnings potentially following in 2027.

As of September, cash and equivalents stood at USD 8.6m, down from USD 10.8m in June. Dependence on ACCRUFeR leaves the business exposed to manufacturing issues, reimbursement decisions, and competitive pressures that could affect revenue trends.

Recent Analyst Coverage
Stifel Europe reiterated a Buy rating on January 12, 2026, assigning a price target of 14.00 GBP. The coverage suggests analysts continue to factor in potential upside while recognising near-term operational and financial risks.